The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of nab-paclitaxel (A), gemcitabine (GEM), and capecitabine (X) in patients with metastatic pancreatic adenocarcinoma (MPA).
Thach-Giao Truong
No relevant relationships to disclose
Margaret A. Tempero
Consultant or Advisory Role - Celgene
Emily Kantoff
No relevant relationships to disclose
Kimberly Jones
No relevant relationships to disclose
Elizabeth Dito
No relevant relationships to disclose
Anna Ong
No relevant relationships to disclose
Andrew H. Ko
Research Funding - Celgene